|
|
|
|
|
|
Late |
Elavarasi et al., medRxiv, doi:10.1101/2021.08.10.21261855 (Preprint) |
death, ↓65.1%, p<0.0001 |
Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India - a cohort study |
|
Details
Retrospective 2017 hospitalized patients in India, showing lower mortality with zinc treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Elavarasi et al., medRxiv, doi:10.1101/2021.08.10.21261855 (Preprint) |
| Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India - a cohort study |
Retrospective 2017 hospitalized patients in India, showing lower mortality with zinc treatment.
risk of death, 65.1% lower, RR 0.35, p < 0.001, treatment 486, control 1201, adjusted, OR converted to RR, model 4, multivariate logistic regression, control prevalence approximated with overall prevalence.
Elavarasi et al., 8/12/2021, retrospective, India, South Asia, preprint, 26 authors.
|
|
Submit Corrections or Comments
|
|
PrEP |
Israel et al., Epidemiology and Global Health Microbiology and Infectious Disease, doi:10.7554/eLife.68165 (Peer Reviewed) |
hosp., ↓>99.9%, p=0.04 |
Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population |
|
Details
Case control study examining medication usage with a healthcare database in Israel, showing lower risk of hospitalization with calcium + zinc supplements (defined as being picked up within 35 days prior to PCR+), however only 10 patients .. |
|
Details
Source
PDF
Pre-Exposure Prophylaxis study
Pre-Exposure Prophylaxis study
|
| Israel et al., Epidemiology and Global Health Microbiology and Infectious Disease, doi:10.7554/eLife.68165 (Peer Reviewed) |
| Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population |
Case control study examining medication usage with a healthcare database in Israel, showing lower risk of hospitalization with calcium + zinc supplements (defined as being picked up within 35 days prior to PCR+), however only 10 patients took the supplements. Other patients may have acquired supplements outside of the healthcare system.
risk of hospitalization, >99.9% lower, RR <0.001, p = 0.04, treatment 0 of 10 (0.0%), control 6953 of 20849 (33.3%), OR converted to RR, continuity correction due to zero event, PCR+, cohort 2.
Israel et al., 7/27/2021, retrospective, Israel, Middle East, peer-reviewed, 10 authors, this trial uses multiple treatments in the treatment arm (combined with calcium) - results of individual treatments may vary.
|
|
Submit Corrections or Comments
|
|
PrEP |
Margolin et al., Journal of Evidence-Based Integrative Medicine, doi:10.1177/2515690X211026193 (Peer Reviewed) |
cases, ↓94.4%, p=0.003 |
20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment |
|
Details
Retrospective 113 outpatients, 53 (patient choice) treated with zinc, quercetin, vitamin C/D/E, l-lysine, and Quina, showing lower cases with treatment. |
|
Details
Source
PDF
Pre-Exposure Prophylaxis study
Pre-Exposure Prophylaxis study
|
| Margolin et al., Journal of Evidence-Based Integrative Medicine, doi:10.1177/2515690X211026193 (Peer Reviewed) |
| 20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment |
Retrospective 113 outpatients, 53 (patient choice) treated with zinc, quercetin, vitamin C/D/E, l-lysine, and Quina, showing lower cases with treatment.
risk of COVID-19 case, 94.4% lower, RR 0.06, p = 0.003, treatment 0 of 53 (0.0%), control 9 of 60 (15.0%), continuity correction due to zero event.
risk of COVID-19 or flu-like illness, 81.1% lower, RR 0.19, p = 0.01, treatment 2 of 53 (3.8%), control 12 of 60 (20.0%).
Margolin et al., 7/6/2021, retrospective, USA, North America, peer-reviewed, 5 authors, this trial uses multiple treatments in the treatment arm (combined with quercetin, vitamin C/D/E, l-lysine, and Quina) - results of individual treatments may vary.
|
|
Submit Corrections or Comments
|
|
Levels |
Beigmohammadi et al., Nutrition, doi:10.1016/j.nut.2021.111400 (Peer Reviewed) |
The association between serum levels of micronutrients and the severity of disease in patients with COVID-19 |
|
Details
Retrospective 60 ICU patients in Iran, showing that lower levels of vitamin D, magnesium, and zinc were significantly associated with higher APACHE scores (P = 0.001, 0.028, and <0.001, respectively) and higher lung involvement (P = 0.002.. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Beigmohammadi et al., Nutrition, doi:10.1016/j.nut.2021.111400 (Peer Reviewed) |
| The association between serum levels of micronutrients and the severity of disease in patients with COVID-19 |
|
Retrospective 60 ICU patients in Iran, showing that lower levels of vitamin D, magnesium, and zinc were significantly associated with higher APACHE scores (P = 0.001, 0.028, and <0.001, respectively) and higher lung involvement (P = 0.002, 0.045, and <0.001, respectively).
Beigmohammadi et al., 6/24/2021, retrospective, Iran, Middle East, peer-reviewed, 8 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Notz et al., Nutrients, doi:10.3390/nu13062113 (Peer Reviewed) |
Clinical Significance of Micronutrient Supplementation in Critically Ill COVID-19 Patients with Severe ARDS |
|
Details
Retrospective 22 ICU patients, showing most patients had low selenium status biomarkers and low zinc levels, and reporting on treatment with nutrient supplementation including selenium and zinc. Authors conclude that sufficient selenium a.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Notz et al., Nutrients, doi:10.3390/nu13062113 (Peer Reviewed) |
| Clinical Significance of Micronutrient Supplementation in Critically Ill COVID-19 Patients with Severe ARDS |
Retrospective 22 ICU patients, showing most patients had low selenium status biomarkers and low zinc levels, and reporting on treatment with nutrient supplementation including selenium and zinc. Authors conclude that sufficient selenium and zinc levels may be important for an adequate immune response in critically ill patients with severe COVID-19 ARDS.
Notz et al., 6/20/2021, retrospective, Germany, Europe, peer-reviewed, 13 authors.
|
|
Submit Corrections or Comments
|
|
In Vitro |
Panchariya et al., bioRxiv, doi:10.1101/2021.06.15.448551 (Preprint) (In Vitro) |
in vitro |
Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro |
|
Details
In Silico and In Vitro study showing that ionic zinc inhibits SARS-CoV-2 main protease (Mpro) and inhibits viral replication.
Zinc acetate inhibited viral replication in Vero E6 cells, while zinc glycinate and zinc gluconate did not at n.. |
|
Details
Source
PDF
In Vitro
In Vitro
|
| Panchariya et al., bioRxiv, doi:10.1101/2021.06.15.448551 (Preprint) (In Vitro) |
| Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro |
In Silico and In Vitro study showing that ionic zinc inhibits SARS-CoV-2 main protease (Mpro) and inhibits viral replication.Zinc acetate inhibited viral replication in Vero E6 cells, while zinc glycinate and zinc gluconate did not at non-toxic concentrations. The combination of zinc acetate with zinc ionophore quercetin signficantly improved inhibition at low concentrations.
Panchariya et al., 6/15/2021, preprint, 14 authors.
|
|
Submit Corrections or Comments
|
|
Levels |
Verschelden et al., medRxiv, doi:10.1101/2021.06.09.21258271 (Preprint) |
Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: an observational study |
|
Details
Prospective study of 139 hospitalized COVID-19 patients, showing 96% had zinc deficiency. Higher zinc levels were associated with a shorter length of hospitalization. Mortality and ventilation was lower with higher zinc levels, but not re.. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Verschelden et al., medRxiv, doi:10.1101/2021.06.09.21258271 (Preprint) |
| Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: an observational study |
Prospective study of 139 hospitalized COVID-19 patients, showing 96% had zinc deficiency. Higher zinc levels were associated with a shorter length of hospitalization. Mortality and ventilation was lower with higher zinc levels, but not reaching statistical significance.
Verschelden et al., 6/12/2021, preprint, 8 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Al Sulaiman et al., Research Square, doi:10.21203/rs.3.rs-572942/v1 (Preprint) |
death, ↓35.0%, p=0.05 |
Evaluation of Zinc Sulfate as an Adjunctive Therapy in COVID-19 Critically Ill Patients: a Two Center Propensity-score Matched Study |
|
Details
Retrospective 266 ICU patients showing lower mortality with zinc treatment (very close to statistical significance), and higher odds of acute kidney injury. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Al Sulaiman et al., Research Square, doi:10.21203/rs.3.rs-572942/v1 (Preprint) |
| Evaluation of Zinc Sulfate as an Adjunctive Therapy in COVID-19 Critically Ill Patients: a Two Center Propensity-score Matched Study |
Retrospective 266 ICU patients showing lower mortality with zinc treatment (very close to statistical significance), and higher odds of acute kidney injury.
risk of death, 35.0% lower, RR 0.65, p = 0.05, treatment 35 of 130 (26.9%), control 45 of 129 (34.9%), adjusted, 30 day, PSM, multivariable Cox proportional hazards.
risk of mechanical ventilation, 23.0% lower, RR 0.77, p = 0.52, treatment 20 of 57 (35.1%), control 23 of 54 (42.6%), adjusted, among non-mechanically ventilated patients within 24 hours of ICU admission.
Al Sulaiman et al., 6/7/2021, retrospective, propensity score matching, Saudi Arabia, Middle East, preprint, 10 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Asimi et al., Endocrine Abstracts, doi:10.1530/endoabs.73.PEP14.2 (Preprint) |
ventilation, ↓97.4%, p<0.0001 |
Selenium, zinc, and vitamin D supplementation affect the clinical course of COVID-19 infection in Hashimoto’s thyroiditis |
|
Details
Retrospective 356 Hashimoto's thyroiditis outpatients, 270 taking vitamin D, zinc, and selenium, showing significantly lower hospitalization with treatment. Authors adjust for age, gender, BMI, and smoking status, reporting statistically .. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Asimi et al., Endocrine Abstracts, doi:10.1530/endoabs.73.PEP14.2 (Preprint) |
| Selenium, zinc, and vitamin D supplementation affect the clinical course of COVID-19 infection in Hashimoto’s thyroiditis |
Retrospective 356 Hashimoto's thyroiditis outpatients, 270 taking vitamin D, zinc, and selenium, showing significantly lower hospitalization with treatment. Authors adjust for age, gender, BMI, and smoking status, reporting statistically significant associations with p<0.001 for hospitalization and mechanical ventilation, however they do not report the adjusted risks.
risk of mechanical ventilation, 97.4% lower, RR 0.03, p < 0.001, treatment 0 of 270 (0.0%), control 9 of 86 (10.5%), continuity correction due to zero event, unadjusted.
risk of hospitalization, 99.0% lower, RR 0.010, p < 0.001, treatment 0 of 270 (0.0%), control 24 of 86 (27.9%), continuity correction due to zero event, unadjusted.
risk of COVID-19 severe case, 99.5% lower, RR 0.005, p < 0.001, treatment 0 of 270 (0.0%), control 51 of 86 (59.3%), continuity correction due to zero event, unadjusted.
Asimi et al., 5/22/2021, retrospective, Bosnia and Herzegovina, Europe, preprint, 3 authors, this trial uses multiple treatments in the treatment arm (combined with vitamin D and selenium) - results of individual treatments may vary.
|
|
Submit Corrections or Comments
|
|
Levels |
Fromonot et al., Clinical Nutrition, doi:10.1016/j.clnu.2021.04.042 (Peer Reviewed) |
hosp., ↓89.2%, p=0.002 |
Hypozincemia in the early stage of COVID-19 is associated with an increased risk of severe COVID-19 |
|
Details
Analysis of 240 consecutive patients in France, showing significantly higher zinc deficiency in COVID-19 patients, and significantly greater risk of hospitalization for COVID-19 patients with zinc deficiency. 2020PI087. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Fromonot et al., Clinical Nutrition, doi:10.1016/j.clnu.2021.04.042 (Peer Reviewed) |
| Hypozincemia in the early stage of COVID-19 is associated with an increased risk of severe COVID-19 |
Analysis of 240 consecutive patients in France, showing significantly higher zinc deficiency in COVID-19 patients, and significantly greater risk of hospitalization for COVID-19 patients with zinc deficiency. 2020PI087.
risk of hospitalization, 89.2% lower, RR 0.11, p = 0.002, treatment 6 of 110 (5.5%), control 7 of 42 (16.7%), OR converted to RR, within COVID-19 patients.
risk of COVID-19 case, 27.6% lower, RR 0.72, p = 0.003, treatment 110 of 188 (58.5%), control 42 of 52 (80.8%).
Fromonot et al., 5/3/2021, prospective, France, Europe, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|
|
Levels |
Skalny et al., Metabolites, doi:10.3390/metabo11040244 (Peer Reviewed) |
Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Severity Markers
|
|
Details
Analysis of serum metal levels in 150 COVID-19 patients and 44 controls, finding that COVID-19 severity was associated with lower serum Ca, Fe, Se, Zn levels when compared to controls. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Skalny et al., Metabolites, doi:10.3390/metabo11040244 (Peer Reviewed) |
| Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Severity Markers
|
Analysis of serum metal levels in 150 COVID-19 patients and 44 controls, finding that COVID-19 severity was associated with lower serum Ca, Fe, Se, Zn levels when compared to controls.
Skalny et al., 4/15/2021, peer-reviewed, 14 authors.
|
|
Submit Corrections or Comments
|
|
PEP |
Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035 (Peer Reviewed) |
severe case, ↓49.7%, p=0.03 |
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial |
|
Details
Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower symptomatic cases, and lower confirmed cases of COVID-19 with all treatments (ivermectin, HCQ, PVP-I, and Zinc + vitamin C) compared to vitamin .. |
|
Details
Source
PDF
Post Exposure Prophylaxis study
Post Exposure Prophylaxis study
|
| Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035 (Peer Reviewed) |
| Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial |
Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower symptomatic cases, and lower confirmed cases of COVID-19 with all treatments (ivermectin, HCQ, PVP-I, and Zinc + vitamin C) compared to vitamin C.Meta-analysis of vitamin C in 6 previous trials shows a benefit of 16%, so the actual benefit of ivermectin, HCQ, and PVP-I may be higher. Cluster RCT with 40 clusters.There were no hospitalizations and no deaths. NCT04446104.
risk of COVID-19 severe case, 49.7% lower, RR 0.50, p = 0.03, treatment 33 of 634 (5.2%), control 64 of 619 (10.3%).
risk of COVID-19 case, 26.9% lower, RR 0.73, p = 0.03, treatment 300 of 634 (47.3%), control 433 of 619 (70.0%), adjusted, OR converted to RR, model 6.
Seet et al., 4/14/2021, Cluster Randomized Controlled Trial, Singapore, Asia, peer-reviewed, 15 authors, this trial compares with another treatment - results may be better when compared to placebo.
|
|
Submit Corrections or Comments
|
|
Late |
Gadhiya et al., BMJ Open, doi:10.1136/bmjopen-2020-042549 (Peer Reviewed) |
death, ↑40.9%, p=0.33 |
Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state |
|
Details
Retrospective 283 patients in the USA showing higher mortality with all treatments (not statistically significant). Confounding by indication is likely. In the supplementary appendix, authors note that the treatments were usually given fo.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Gadhiya et al., BMJ Open, doi:10.1136/bmjopen-2020-042549 (Peer Reviewed) |
| Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state |
Retrospective 283 patients in the USA showing higher mortality with all treatments (not statistically significant). Confounding by indication is likely. In the supplementary appendix, authors note that the treatments were usually given for patients that required oxygen therapy. Oxygen therapy and ICU admission (possibly, the paper includes ICU admission for model 2 in some places but not others) were the only variables indicating severity used in adjustments.
risk of death, 40.9% higher, RR 1.41, p = 0.33, treatment 21 of 54 (38.9%), control 34 of 229 (14.8%), adjusted, OR converted to RR, multivariate logistic regression.
Gadhiya et al., 4/8/2021, retrospective, USA, North America, peer-reviewed, 4 authors.
|
|
Submit Corrections or Comments
|
|
Levels |
Dubourg et al., Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2021.01.012 (Peer Reviewed) |
Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with Zinc COVID-19 patients? |
|
Details
Retrospective 275 patients showing zinc levels significantly lower in patients with poor outcomes, 840 vs. 970 µg/L, p< 0.0001. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Dubourg et al., Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2021.01.012 (Peer Reviewed) |
| Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with Zinc COVID-19 patients? |
Retrospective 275 patients showing zinc levels significantly lower in patients with poor outcomes, 840 vs. 970 µg/L, p< 0.0001.
Dubourg et al., 2/13/2021, peer-reviewed, 8 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Thomas et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.0369 (Peer Reviewed) |
recov. time, ↓11.9%, p=0.38 |
Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial |
|
Details
Small 214 low-risk outpatient RCT showing non-statistically significant faster recovery with zinc and with vitamin C. The zinc dosage appears low, 50mg zinc glcuonate (7mg elemental zinc). Study performed in the USA where zinc deficiency .. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Thomas et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.0369 (Peer Reviewed) |
| Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial |
Small 214 low-risk outpatient RCT showing non-statistically significant faster recovery with zinc and with vitamin C. The zinc dosage appears low, 50mg zinc glcuonate (7mg elemental zinc). Study performed in the USA where zinc deficiency is relatively uncommon. NCT04342728.The dose of zinc is a tenth of that shown to reduce duration of colds in other studies [1].
recovery time, 11.9% lower, relative time 0.88, p = 0.38, treatment 58, control 50, mean time to a 50% reduction in symptoms, p value approximated with combined p value in study.
Thomas et al., 2/12/2021, Randomized Controlled Trial, USA, North America, peer-reviewed, 11 authors.
|
|
Submit Corrections or Comments
|
|
Review |
Sethuram et al., Reproductive Sciences, doi:10.1007/s43032-020-00400-6 (Review) (Peer Reviewed) |
review |
Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction |
|
Details
Review of zinc deficiency and supplementation for COVID-19, including potential impacts on reproductive health. |
|
Details
Source
PDF
Review
Review
|
| Sethuram et al., Reproductive Sciences, doi:10.1007/s43032-020-00400-6 (Review) (Peer Reviewed) |
| Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction |
Review of zinc deficiency and supplementation for COVID-19, including potential impacts on reproductive health.
Sethuram et al., 1/7/2021, peer-reviewed, 3 authors.
|
|
Submit Corrections or Comments
|
|
Review |
Joachimiak et al., PLOS Neglected Tropical Diseases, doi:10.1371/journal.pntd.0008895 (Review) (Peer Reviewed) |
review |
Zinc against COVID-19? Symptom surveillance and deficiency risk groups |
|
Details
Literature review concluding that zinc should be included as part of preventative supplementation for COVID-19, in general for support of immune health, and should also be considered in the context of zinc deficiency acquired during a vir.. |
|
Details
Source
PDF
Review
Review
|
| Joachimiak et al., PLOS Neglected Tropical Diseases, doi:10.1371/journal.pntd.0008895 (Review) (Peer Reviewed) |
| Zinc against COVID-19? Symptom surveillance and deficiency risk groups |
Literature review concluding that zinc should be included as part of preventative supplementation for COVID-19, in general for support of immune health, and should also be considered in the context of zinc deficiency acquired during a viral infection and host immune response.
Joachimiak et al., 1/4/2021, peer-reviewed, 1 author.
|
|
Submit Corrections or Comments
|
|
Review |
McCullough et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.264 (Review) (Peer Reviewed) |
review |
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) |
|
Details
Review urging early treatment of COVID-19 with sequential multidrug treatment that has been shown to be safe and effective. Proposed treatment includes zinc, vitamin D & C, quercetin, and depending on age, comorbidities, and symptoms may .. |
|
Details
Source
PDF
Review
Review
|
| McCullough et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.264 (Review) (Peer Reviewed) |
| Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) |
|
Review urging early treatment of COVID-19 with sequential multidrug treatment that has been shown to be safe and effective. Proposed treatment includes zinc, vitamin D & C, quercetin, and depending on age, comorbidities, and symptoms may include >=2 of HCQ, ivermectin, favipiravir; AZM/DOXY; corticosteroids; colchicine; bamlanivimab; aspirin; LMWH; and supplemental oxygen.
McCullough et al., 12/30/2020, peer-reviewed, 58 authors.
|
|
Submit Corrections or Comments
|
|
Levels |
Gonçalves et al., Nutrition in Clinical Practice, doi:10.1002/ncp.10612 (Peer Reviewed) |
severe case, ↓82.3%, p<0.001 |
Association Between Low Zinc Levels and Severity of Acute Respiratory Distress Syndrome by New Coronavirus SARS-CoV-2 |
|
Details
Retrospective 169 ICU patients in Brazil, 214 with low zinc levels, showing an association between low zinc levels and severe ARDS. CAAE 30608,020.9.0000.8114. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Gonçalves et al., Nutrition in Clinical Practice, doi:10.1002/ncp.10612 (Peer Reviewed) |
| Association Between Low Zinc Levels and Severity of Acute Respiratory Distress Syndrome by New Coronavirus SARS-CoV-2 |
Retrospective 169 ICU patients in Brazil, 214 with low zinc levels, showing an association between low zinc levels and severe ARDS. CAAE 30608,020.9.0000.8114.
risk of COVID-19 severe case, 82.3% lower, RR 0.18, p < 0.001, treatment 7 of 55 (12.7%), control 145 of 214 (67.8%), adjusted, OR converted to RR, ≥70 μg/dL, logistic regression.
Gonçalves et al., 12/23/2020, retrospective, Brazil, South America, peer-reviewed, 9 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Darban et al., Journal of Cellular & Molecular Anesthesia, doi:10.22037/jcma.v6i2.32182 (Peer Reviewed) |
progression, ↓33.3%, p=1.00 |
Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial |
|
Details
Small RCT in Iran with 20 ICU patients, 10 treated with high-dose vitamin C, melatonin, and zinc, not showing significant differences. IRCT20151228025732N52. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Darban et al., Journal of Cellular & Molecular Anesthesia, doi:10.22037/jcma.v6i2.32182 (Peer Reviewed) |
| Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial |
Small RCT in Iran with 20 ICU patients, 10 treated with high-dose vitamin C, melatonin, and zinc, not showing significant differences. IRCT20151228025732N52.
risk of disease progression, 33.3% lower, RR 0.67, p = 1.00, treatment 2 of 10 (20.0%), control 3 of 10 (30.0%).
ICU time, 6.0% lower, relative time 0.94, p = 0.30, treatment 10, control 10.
Darban et al., 12/15/2020, Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 8 authors, this trial uses multiple treatments in the treatment arm (combined with melatonin and vitamin C) - results of individual treatments may vary.
|
|
Submit Corrections or Comments
|
|
PrEP |
Louca et al., BMJ Nutrition, Prevention & Health, doi:10.1136/bmjnph-2021-000250 (preprint 11/30/20) (Peer Reviewed) |
cases, ↓0.9%, p=0.80 |
Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study app |
|
Details
Survey analysis of dietary supplements showing no significant difference in PCR+ cases with zinc usage. These results are for PCR+ cases only, they do not reflect potential benefits for reducing the severity of cases. A number of biases c.. |
|
Details
Source
PDF
Pre-Exposure Prophylaxis study
Pre-Exposure Prophylaxis study
|
| Louca et al., BMJ Nutrition, Prevention & Health, doi:10.1136/bmjnph-2021-000250 (preprint 11/30/20) (Peer Reviewed) |
| Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study app |
Survey analysis of dietary supplements showing no significant difference in PCR+ cases with zinc usage. These results are for PCR+ cases only, they do not reflect potential benefits for reducing the severity of cases. A number of biases could affect the results, for example users of the app may not be representative of the general population, and people experiencing symptoms may be more likely to install and use the app.
risk of COVID-19 case, 0.9% lower, RR 0.99, p = 0.80, OR converted to RR, United Kingdom, all adjustment model.
Louca et al., 11/30/2020, retrospective, United Kingdom, Europe, peer-reviewed, 26 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Abd-Elsalam et al., Biological Trace Element Research, doi:10.1007/s12011-020-02512-1 (Peer Reviewed) |
death, ↓1.0%, p=0.99 |
Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial |
|
Details
191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant difference.
Clinical recovery at 28 days was 79.2% in the zinc group and 77.9% control, p = 0.969.
Mechanical ventilation was used with 4 patients.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Abd-Elsalam et al., Biological Trace Element Research, doi:10.1007/s12011-020-02512-1 (Peer Reviewed) |
| Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial |
191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant difference.Clinical recovery at 28 days was 79.2% in the zinc group and 77.9% control, p = 0.969.Mechanical ventilation was used with 4 patients in the zinc group and 6 control. There were 5 deaths in each group.No information on baseline zinc values was recorded. We note that Egypt has a low rate of zinc deficiency so supplementation is less likely to be helpful in Egypt [1, 2]
risk of death, 1.0% lower, RR 0.99, p = 0.99, treatment 5 of 96 (5.2%), control 5 of 95 (5.3%).
risk of mechanical ventilation, 34.0% lower, RR 0.66, p = 0.54, treatment 4 of 96 (4.2%), control 6 of 95 (6.3%).
risk of no recovery, 5.8% lower, RR 0.94, p = 0.97, treatment 20 of 96 (20.8%), control 21 of 95 (22.1%).
hospitalization time, 3.6% lower, relative time 0.96, p = 0.55, treatment 96, control 95.
Abd-Elsalam et al., 11/29/2020, Randomized Controlled Trial, Egypt, Africa, peer-reviewed, 10 authors.
|
|
Submit Corrections or Comments
|
|
In Silico |
Pormohammad et al., International Journal of Molecular Medicine, doi:10.3892/ijmm.2020.4790 (Peer Reviewed) |
Zinc and SARS‑CoV‑2: A molecular modeling study of Zn interactions with RNA‑dependent RNA‑polymerase and 3C‑like proteinase enzymes |
|
Details
In Silico analysis supporting the hypothesis that Zn would bind and regulate the enzymatic activities of 3CLpro and RdRp of SARS‑CoV-2 and therefore inhibit viral replication. Since Zn has established immune health benefits, is readily av.. |
|
Details
Source
PDF
In Silico
In Silico
|
| Pormohammad et al., International Journal of Molecular Medicine, doi:10.3892/ijmm.2020.4790 (Peer Reviewed) |
| Zinc and SARS‑CoV‑2: A molecular modeling study of Zn interactions with RNA‑dependent RNA‑polymerase and 3C‑like proteinase enzymes |
In Silico analysis supporting the hypothesis that Zn would bind and regulate the enzymatic activities of 3CLpro and RdRp of SARS‑CoV-2 and therefore inhibit viral replication. Since Zn has established immune health benefits, is readily available, inexpensive and safe, the authors propose that Zn could help ameliorate COVID-19.
Pormohammad et al., 11/18/2020, peer-reviewed, 3 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Frontera et al., Research Square, doi:10.21203/rs.3.rs-94509/v1 (Preprint) |
death, ↓37.0%, p=0.01 |
Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study |
|
Details
Retrospective 3,473 hospitalized patients showing 37% lower mortality with HCQ+zinc.
PSM aHR 0.63, p=0.015
regression aHR 0.76, p = 0.023 |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Frontera et al., Research Square, doi:10.21203/rs.3.rs-94509/v1 (Preprint) |
| Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study |
Retrospective 3,473 hospitalized patients showing 37% lower mortality with HCQ+zinc.PSM aHR 0.63, p=0.015 regression aHR 0.76, p = 0.023
risk of death, 37.0% lower, RR 0.63, p = 0.01, treatment 121 of 1006 (12.0%), control 424 of 2467 (17.2%), adjusted, PSM.
risk of death, 24.0% lower, RR 0.76, p = 0.02, treatment 121 of 1006 (12.0%), control 424 of 2467 (17.2%), adjusted, regression.
Frontera et al., 10/26/2020, retrospective, propensity score matching, USA, North America, preprint, median age 64.0, 14 authors, this trial uses multiple treatments in the treatment arm (combined with HCQ) - results of individual treatments may vary.
|
|
Submit Corrections or Comments
|
|
Levels |
Berrocal et al., Research Square, doi:10.21203/rs.3.rs-95524/v1 (Preprint) |
death, ↓44.8%, p=0.23 |
Zinc and Vitamin A Deficiency Predisposes to the Need for Intubation and ICU Admission in Patients With COVID-19. An Observational Study |
|
Details
Retrospective 120 hospitalized patients showing zinc deficiency associated with higher ICU admission. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Berrocal et al., Research Square, doi:10.21203/rs.3.rs-95524/v1 (Preprint) |
| Zinc and Vitamin A Deficiency Predisposes to the Need for Intubation and ICU Admission in Patients With COVID-19. An Observational Study |
Retrospective 120 hospitalized patients showing zinc deficiency associated with higher ICU admission.
risk of death, 44.8% lower, RR 0.55, p = 0.23, treatment 5 of 31 (16.1%), control 26 of 89 (29.2%), ≥84 mcg/dL.
risk of ICU admission, 53.0% lower, RR 0.47, p = 0.003, treatment 9 of 31 (29.0%), control 55 of 89 (61.8%), ≥84 mcg/dL.
Berrocal et al., 10/26/2020, retrospective, Spain, Europe, preprint, 7 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3) (Peer Reviewed) |
death, ↓79.4%, p=0.12 |
COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study |
|
Details
79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. Retrospective 518 patients (141 treated, 377 control). |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3) (Peer Reviewed) |
| COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study |
79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. Retrospective 518 patients (141 treated, 377 control).
risk of death, 79.4% lower, RR 0.21, p = 0.12, treatment 1 of 141 (0.7%), control 13 of 377 (3.4%), OR converted to RR.
risk of hospitalization, 81.6% lower, RR 0.18, p < 0.001, treatment 4 of 141 (2.8%), control 58 of 377 (15.4%), OR converted to RR.
Derwand et al., 10/26/2020, retrospective, USA, North America, peer-reviewed, 3 authors.
|
|
Submit Corrections or Comments
|
|
PrEP |
Heller et al., Redox Biology, doi:10.1016/j.redox.2020.101764 (Peer Reviewed) |
Prediction of Survival Odds in COVID-19 by Zinc, Age and Selenoprotein P as Composite Biomarker |
|
Details
Analysis of 35 COVID-19 patients showing a significant correlation for serum zinc levels between COVID-19 patients and controls, and between COVID-19 survivors and non-survivors. |
|
Details
Source
PDF
Pre-Exposure Prophylaxis study
Pre-Exposure Prophylaxis study
|
| Heller et al., Redox Biology, doi:10.1016/j.redox.2020.101764 (Peer Reviewed) |
| Prediction of Survival Odds in COVID-19 by Zinc, Age and Selenoprotein P as Composite Biomarker |
Analysis of 35 COVID-19 patients showing a significant correlation for serum zinc levels between COVID-19 patients and controls, and between COVID-19 survivors and non-survivors.
Heller et al., 10/20/2020, peer-reviewed, 14 authors.
|
|
Submit Corrections or Comments
|
|
Levels |
Vogel-González et al., Nutrients, doi:10.3390/nu13020562 (preprint 10/11/2020) (Peer Reviewed) |
death, ↓77.2%, p=0.0005 |
Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection |
|
Details
Retrospective 249 PCR+ hospitalized patients in Spain, 58 with zinc levels on admission <50 μg/dL, showing higher mortality and ICU admission, and slower recovery with low zinc levels. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Vogel-González et al., Nutrients, doi:10.3390/nu13020562 (preprint 10/11/2020) (Peer Reviewed) |
| Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection |
Retrospective 249 PCR+ hospitalized patients in Spain, 58 with zinc levels on admission <50 μg/dL, showing higher mortality and ICU admission, and slower recovery with low zinc levels.
risk of death, 77.2% lower, RR 0.23, p < 0.001, treatment 9 of 191 (4.7%), control 12 of 58 (20.7%), ≥50 μg/dL.
risk of ICU admission, 71.3% lower, RR 0.29, p < 0.001, treatment 34 of 191 (17.8%), control 36 of 58 (62.1%), ≥50 μg/dL.
recovery time, 68.0% lower, relative time 0.32, p < 0.001, treatment 191, control 58, ≥50 μg/dL.
Vogel-González et al., 10/11/2020, retrospective, Spain, Europe, peer-reviewed, 16 authors.
|
|
Submit Corrections or Comments
|
|
Levels |
Jothimani (Peer Reviewed) |
death, ↓89.7%, p=0.06 |
COVID-19: Poor outcomes in patients with zinc deficiency |
|
Details
Prospective study of zinc levels in 47 hospitalized COVID-19 patients and 45 healthy controls. COVID-19 patients had significantly lower zinc levels (74.5 vs. 105.8 median μg/dl, p < 0.001). 57.4% of COVID-19 patients were zinc deficient,.. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Jothimani (Peer Reviewed) |
| COVID-19: Poor outcomes in patients with zinc deficiency |
Prospective study of zinc levels in 47 hospitalized COVID-19 patients and 45 healthy controls. COVID-19 patients had significantly lower zinc levels (74.5 vs. 105.8 median μg/dl, p < 0.001). 57.4% of COVID-19 patients were zinc deficient, and they had higher rates of complications, ARDS, prolonged hospital stay, and increased mortality.
risk of death, 89.7% lower, RR 0.10, p = 0.06, treatment 0 of 20 (0.0%), control 5 of 27 (18.5%), continuity correction due to zero event.
risk of ICU admission, 92.4% lower, RR 0.08, p = 0.02, treatment 0 of 20 (0.0%), control 7 of 27 (25.9%), continuity correction due to zero event.
Jothimani et al., 9/10/2020, prospective, India, South Asia, peer-reviewed, 11 authors.
|
|
Submit Corrections or Comments
|
|
Levels |
Yasui et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.09.008 (Peer Reviewed) |
ventilation, ↓92.5%, p=0.001 |
Analysis of the predictive factors for a critical illness of COVID-19 during treatment - relationship between serum zinc level and critical illness of COVID-19 |
|
Details
Retrospective 62 hospitalized patients, 29 with serum zinc data, showing significantly lower serum zinc levels for severe COVID-19 cases (intubation) compared with mild and moderate cases, p = 0.005. Authors recommend zinc supplementation. |
|
Details
Source
PDF
Levels
Analysis of outcomes based on serum levels
|
| Yasui et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.09.008 (Peer Reviewed) |
| Analysis of the predictive factors for a critical illness of COVID-19 during treatment - relationship between serum zinc level and critical illness of COVID-19 |
Retrospective 62 hospitalized patients, 29 with serum zinc data, showing significantly lower serum zinc levels for severe COVID-19 cases (intubation) compared with mild and moderate cases, p = 0.005. Authors recommend zinc supplementation.
risk of mechanical ventilation, 92.5% lower, RR 0.08, p = 0.001, treatment 1 of 20 (5.0%), control 6 of 9 (66.7%), zinc >= 70μg/dL.
Yasui et al., 9/7/2020, retrospective, Japan, Asia, peer-reviewed, 10 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Yao et al., Chest, doi:10.1016/j.chest.2020.06.082 (Peer Reviewed) |
death, ↓34.0%, p=0.09 |
The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19 |
|
Details
Retrospective 242 hospitalized patients in the USA showing adjusted hazard ratio for zinc treatment, aHR 0.66 [0.41-1.07]. [1] notes that the study would be more informative if baseline serum zinc levels were known. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Yao et al., Chest, doi:10.1016/j.chest.2020.06.082 (Peer Reviewed) |
| The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19 |
Retrospective 242 hospitalized patients in the USA showing adjusted hazard ratio for zinc treatment, aHR 0.66 [0.41-1.07]. [1] notes that the study would be more informative if baseline serum zinc levels were known.
risk of death, 34.0% lower, RR 0.66, p = 0.09, treatment 73 of 196 (37.2%), control 21 of 46 (45.7%), adjusted, multivariate Cox regression.
Yao et al., 7/22/2020, retrospective, USA, North America, peer-reviewed, 9 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Krishnan et al., J Clin Anesth., doi:10.1016/j.jclinane.2020.110005 (Peer Reviewed) |
death, ↓17.6%, p=0.18 |
Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia |
|
Details
Retrospective 152 mechanically ventilated patients in the USA showing unadjusted lower mortality with vitamin C, vitamin D, HCQ, and zinc treatment, statistically significant only for vitamin C. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Krishnan et al., J Clin Anesth., doi:10.1016/j.jclinane.2020.110005 (Peer Reviewed) |
| Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia |
Retrospective 152 mechanically ventilated patients in the USA showing unadjusted lower mortality with vitamin C, vitamin D, HCQ, and zinc treatment, statistically significant only for vitamin C.
risk of death, 17.6% lower, RR 0.82, p = 0.18, treatment 31 of 58 (53.4%), control 61 of 94 (64.9%).
Krishnan et al., 7/20/2020, retrospective, USA, North America, peer-reviewed, 13 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Finzi et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.006 (Peer Reviewed) |
Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients |
|
Details
Case report on 4 patients treated with high dose zinc. All patients experienced significant improvement after one day. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Finzi et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.006 (Peer Reviewed) |
| Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients |
Case report on 4 patients treated with high dose zinc. All patients experienced significant improvement after one day.
Finzi et al., 6/6/2020, peer-reviewed, 1 author.
|
|
Submit Corrections or Comments
|
|
Late |
Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed) |
death/HPC, ↓37.7%, p=0.002 |
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients |
|
Details
Retrospective 932 patients showing that the addition of zinc to HCQ+AZ reduced mortality / transfer to hospice, ICU admission, and the need for ventilation. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed) |
| Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients |
Retrospective 932 patients showing that the addition of zinc to HCQ+AZ reduced mortality / transfer to hospice, ICU admission, and the need for ventilation.
risk of combined death/hospice, 37.7% lower, RR 0.62, p = 0.002, treatment 54 of 411 (13.1%), control 119 of 521 (22.8%), adjusted, OR converted to RR, multivariate logistic regression.
risk of mechanical ventilation, 18.0% lower, RR 0.82, p = 0.40, treatment 29 of 411 (7.1%), control 62 of 521 (11.9%), adjusted, OR converted to RR, multivariate logistic regression.
risk of ICU admission, 23.5% lower, RR 0.77, p = 0.17, treatment 38 of 411 (9.2%), control 82 of 521 (15.7%), adjusted, OR converted to RR, multivariate logistic regression.
Carlucci et al., 5/8/2020, retrospective, USA, North America, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|
|
In Vitro |
te Velthuis et al., PLOS Pathogens 2010, 6:11, doi:10.1371/journal.ppat.1001176 (Peer Reviewed) (In Vitro) |
in vitro |
Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture |
|
Details
Shows that the combination of Zn2+ and a zinc ionophore (pyrithione) at low concentrations inhibits the replication of SARS-CoV and equine arteritis virus (EAV) in cell culture. Recommends further study of the use of zinc-ionophores as an.. |
|
Details
Source
PDF
In Vitro
In Vitro
|
| te Velthuis et al., PLOS Pathogens 2010, 6:11, doi:10.1371/journal.ppat.1001176 (Peer Reviewed) (In Vitro) |
| Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture |
|
Shows that the combination of Zn2+ and a zinc ionophore (pyrithione) at low concentrations inhibits the replication of SARS-CoV and equine arteritis virus (EAV) in cell culture. Recommends further study of the use of zinc-ionophores as antiviral compounds.
te Velthuis et al., 1/1/2010, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|